Novavax Begins Test on New Vaccine Technology
Share prices for biotech vaccine developer Novavax Inc. (NASDAQ: NVAX) climbed a respectable 8 percent over the course of the day today, thanks to the news that the company has started the first human clinical trial of its vaccine for the pandemic flu virus. According to the latest statement from the company, Novavax has begun vaccinating 230 healthy human volunteers for the trial of its Virus-Like Particle (VLP)-based H5N1 clade 2 pandemic influenza vaccine to determine both the safety and immunogenicity - that is, the ability of any particular substance in a biological system to provoke an immune response -…